Novartis (NVS) Revenue & Revenue Breakdown
Novartis Revenue Highlights
Latest Revenue (Y)
$46.66B
Latest Revenue (Q)
$11.83B
Main Segment (Y)
Top 20 products
Main Geography (Y)
Americas
Novartis Revenue by Period
Novartis Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $46.66B | -9.97% |
| 2022-12-31 | $51.83B | -1.98% |
| 2021-12-31 | $52.88B | 5.97% |
| 2020-12-31 | $49.90B | 2.51% |
| 2019-12-31 | $48.68B | -8.44% |
| 2018-12-31 | $53.17B | 6.05% |
| 2017-12-31 | $50.13B | 1.41% |
| 2016-12-31 | $49.44B | -1.89% |
| 2015-12-31 | $50.39B | -6.05% |
| 2014-12-31 | $53.63B | -8.83% |
| 2013-12-31 | $58.83B | 2.21% |
| 2012-12-31 | $57.56B | -3.06% |
| 2011-12-31 | $59.38B | 15.15% |
| 2010-12-31 | $51.56B | 14.32% |
| 2009-12-31 | $45.10B | 5.92% |
| 2008-12-31 | $42.58B | 9.34% |
| 2007-12-31 | $38.95B | 5.98% |
| 2006-12-31 | $36.75B | 12.98% |
| 2005-12-31 | $32.53B | 15.15% |
| 2004-12-31 | $28.25B | 13.61% |
| 2003-12-31 | $24.86B | 7.40% |
| 2002-12-31 | $23.15B | 19.74% |
| 2001-12-31 | $19.34B | -11.44% |
| 2000-12-31 | $21.83B | 6.93% |
| 1999-12-31 | $20.42B | -11.38% |
| 1998-12-31 | $23.04B | - |
Novartis generated $46.66B in revenue during NA 2023, up -9.97% compared to the previous quarter, and up 87.76% compared to the same period a year ago.
Novartis Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $11.83B | 0.45% |
| 2023-12-31 | $11.78B | -2.61% |
| 2023-09-30 | $12.09B | -13.23% |
| 2023-06-30 | $13.94B | 5.51% |
| 2023-03-31 | $13.21B | 0.92% |
| 2022-12-31 | $13.09B | 1.91% |
| 2022-09-30 | $12.84B | -1.86% |
| 2022-06-30 | $13.09B | 2.11% |
| 2022-03-31 | $12.81B | -5.24% |
| 2021-12-31 | $13.52B | 1.16% |
| 2021-09-30 | $13.37B | 0.55% |
| 2021-06-30 | $13.29B | 4.73% |
| 2021-03-31 | $12.69B | -2.58% |
| 2020-12-31 | $13.03B | 3.92% |
| 2020-09-30 | $12.54B | 7.88% |
| 2020-06-30 | $11.62B | -8.55% |
| 2020-03-31 | $12.71B | -0.06% |
| 2019-12-31 | $12.72B | 1.87% |
| 2019-09-30 | $12.48B | 3.81% |
| 2019-06-30 | $12.02B | 4.97% |
| 2019-03-31 | $11.46B | -16.17% |
| 2018-12-31 | $13.66B | 20.01% |
| 2018-09-30 | $11.39B | -15.36% |
| 2018-06-30 | $13.45B | 4.05% |
| 2018-03-31 | $12.93B | -1.79% |
| 2017-12-31 | $13.16B | 3.72% |
| 2017-09-30 | $12.69B | 1.58% |
| 2017-06-30 | $12.49B | 6.02% |
| 2017-03-31 | $11.79B | -6.51% |
| 2016-12-31 | $12.61B | 2.15% |
| 2016-09-30 | $12.34B | -2.67% |
| 2016-06-30 | $12.68B | 7.36% |
| 2016-03-31 | $11.81B | -7.76% |
| 2015-12-31 | $12.80B | 2.56% |
| 2015-09-30 | $12.48B | -3.19% |
| 2015-06-30 | $12.90B | 5.69% |
| 2015-03-31 | $12.20B | -8.63% |
| 2014-12-31 | $13.35B | 0.41% |
| 2014-09-30 | $13.30B | -4.65% |
| 2014-06-30 | $13.95B | -2.04% |
| 2014-03-31 | $14.24B | -7.32% |
| 2013-12-31 | $15.36B | 5.53% |
| 2013-09-30 | $14.56B | -0.99% |
| 2013-06-30 | $14.70B | 3.51% |
| 2013-03-31 | $14.21B | -5.72% |
| 2012-12-31 | $15.07B | 7.33% |
| 2012-09-30 | $14.04B | -3.45% |
| 2012-06-30 | $14.54B | 4.51% |
| 2012-03-31 | $13.91B | -7.22% |
| 2011-12-31 | $15.00B | -0.25% |
| 2011-09-30 | $15.03B | -0.59% |
| 2011-06-30 | $15.12B | 6.34% |
| 2011-03-31 | $14.22B | -1.67% |
| 2010-12-31 | $14.46B | 12.82% |
| 2010-09-30 | $12.82B | 7.54% |
| 2010-06-30 | $11.92B | -3.52% |
| 2010-03-31 | $12.36B | -6.00% |
| 2009-12-31 | $13.14B | 16.43% |
| 2009-09-30 | $11.29B | 5.10% |
| 2009-06-30 | $10.74B | 8.22% |
| 2009-03-31 | $9.93B | -4.08% |
| 2008-12-31 | $10.35B | -6.18% |
| 2008-09-30 | $11.03B | 2.83% |
| 2008-06-30 | $10.73B | 4.99% |
| 2008-03-31 | $10.22B | 0.44% |
| 2007-12-31 | $10.17B | - |
Novartis generated $11.83B in revenue during Q1 2024, up 0.45% compared to the previous quarter, and up 90.39% compared to the same period a year ago.
Novartis Revenue Breakdown
Novartis Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 22 | Dec 21 | Dec 20 | Dec 19 | Dec 18 |
|---|---|---|---|---|---|
| Total anti-infectives net sales | $1.20B | $1.10B | - | - | - |
| Top 20 products | $32.14B | $32.66B | $29.92B | $28.65B | $26.95B |
| Anti Infectives sold under Sandoz name | $777.00M | $707.00M | $694.00M | $784.00M | - |
| Rest of portfolio | $9.16B | $9.33B | $9.10B | $9.07B | $7.95B |
| COPD | - | - | - | $427.00M | - |
Novartis's latest annual revenue breakdown by segment (product or service), as of Dec 22: Top 20 products (74.27%), Rest of portfolio (21.17%), Total anti-infectives net sales (2.77%), and Anti Infectives sold under Sandoz name (1.80%).
Quarterly Revenue by Product
| Product/Service | Jun 23 | Jun 22 | Jun 21 | Jun 20 | Jun 19 |
|---|---|---|---|---|---|
| Rest of portfolio | $2.45B | $2.20B | $2.33B | $2.08B | $2.12B |
| Top 20 products | $8.79B | $8.26B | $8.23B | $7.10B | $7.21B |
| Anti Infectives sold under Sandoz name | - | $183.00M | $161.00M | $134.00M | - |
| Total anti-infectives net sales | - | $276.00M | $257.00M | - | - |
Novartis's latest quarterly revenue breakdown by segment (product or service), as of Jun 23: Top 20 products (78.18%), and Rest of portfolio (21.82%).
Novartis Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 22 | Dec 21 | Dec 20 | Dec 19 | Dec 18 |
|---|---|---|---|---|---|
| Other countries | $20.05B | $20.81B | $19.04B | $21.10B | $22.17B |
| Country of domicile | $970.00M | $873.00M | $800.00M | $848.00M | $852.00M |
| CHINA | $3.13B | $3.05B | $2.57B | - | - |
| JAPAN | $2.21B | $2.68B | $2.80B | $2.66B | $3.17B |
| GERMANY | $4.28B | $4.87B | $4.52B | $4.12B | $4.18B |
| FRANCE | $2.26B | $2.52B | $2.44B | $2.44B | $2.71B |
| Americas | $21.54B | $20.46B | $19.73B | - | - |
| Europe | - | - | - | $5.12B | - |
| US | - | - | - | $2.49B | - |
| UNITED STATES | - | - | - | $16.28B | $17.56B |
| Asia/Africa/Australasia | - | - | - | $1.34B | - |
| Canada and Latin America | - | - | - | $784.00M | - |
Novartis's latest annual revenue breakdown by geography, as of Dec 22: Americas (39.57%), Other countries (36.85%), GERMANY (7.86%), CHINA (5.75%), FRANCE (4.15%), JAPAN (4.05%), and Country of domicile (1.78%).
Quarterly Revenue by Country
| Country | Jun 19 |
|---|---|
| Asia/Africa/Australasia | $333.00M |
Novartis's latest quarterly revenue breakdown by geography, as of Jun 19: Asia/Africa/Australasia (100.00%).
Novartis Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| JNJ | Johnson & Johnson | $85.15B | $22.45B |
| MRK | Merck | $60.12B | $16.11B |
| PFE | Pfizer | $58.50B | $13.28B |
| ABBV | AbbVie | $54.32B | $14.46B |
| NVS | Novartis | $46.66B | $11.83B |
| AZN | AstraZeneca | $45.81B | $12.68B |
| BMY | Bristol-Myers Squibb Company | $45.01B | $12.20B |
| SNY | Sanofi | $43.07B | $11.12B |
| LLY | Eli Lilly and Company | $34.12B | $11.30B |
| GSK | GSK | $30.33B | $7.36B |
| GILD | Gilead Sciences | $27.12B | $6.95B |
NVS Revenue FAQ
What is Novartis’s yearly revenue?
Novartis's yearly revenue for 2023 was $46.66B, representing a decrease of -9.97% compared to 2022. The company's yearly revenue for 2022 was $51.83B, representing a decrease of -1.98% compared to 2021. NVS's yearly revenue for 2021 was $52.88B, representing an increase of 5.97% compared to 2020.
What is Novartis’s quarterly revenue?
Novartis's quarterly revenue for Q1 2024 was $11.83B, a 0.45% increase from the previous quarter (Q4 2023), and a -10.44% decrease year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $11.78B, a -2.61% decrease from the previous quarter (Q3 2023), and a -10.02% decrease year-over-year (Q4 2022). NVS's quarterly revenue for Q3 2023 was $12.09B, a -13.23% decrease from the previous quarter (Q2 2023), and a -5.84% decrease year-over-year (Q3 2022).
What is Novartis’s revenue growth rate?
Novartis's revenue growth rate for the last 3 years (2021-2023) was -11.76%, and for the last 5 years (2019-2023) was -4.14%.
What are Novartis’s revenue streams?
Novartis's revenue streams in c 22 are Total anti-infectives net sales, Top 20 products, Anti Infectives sold under Sandoz name, and Rest of portfolio. Total anti-infectives net sales generated $1.2B in revenue, accounting 2.77% of the company's total revenue, up 9.09% year-over-year. Top 20 products generated $32.14B in revenue, accounting 74.27% of the company's total revenue, down -1.61% year-over-year. Anti Infectives sold under Sandoz name generated $777M in revenue, accounting 1.80% of the company's total revenue, up 9.90% year-over-year. Rest of portfolio generated $9.16B in revenue, accounting 21.17% of the company's total revenue, down -1.84% year-over-year.
What is Novartis’s main source of revenue?
For the fiscal year ending Dec 22, the largest source of revenue of Novartis was Top 20 products. This segment made a revenue of $32.14B, representing 74.27% of the company's total revenue.